Skip to main content
Idorsia Ltd logo

Idorsia Ltd — Investor Relations & Filings

Ticker · IDIA ISIN · CH0363463438 LEI · 506700XOVZUB107S5720 SW Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2025-03-03 Management Reports
Country CH Switzerland
Listing SW IDIA

About Idorsia Ltd

https://www.idorsia.com/index

Idorsia Ltd is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative small-molecule medicines. The company maintains a diversified and balanced clinical development pipeline targeting multiple therapeutic areas. These areas include central nervous system (CNS) disorders, cardiovascular conditions, immunological diseases, and orphan diseases. Idorsia's objective is to develop new products that can significantly alter treatment options in their target indications. A key commercialized product is a dual orexin receptor antagonist for the treatment of insomnia.

Recent filings

Filing Released Lang Actions
Management Reports 2025
Management Reports Classification · 95% confidence The document is a detailed financial review section extracted from the Idorsia Annual Report 2024. It contains comprehensive financial tables, including profit and loss, cash flow, liquidity, and operational performance metrics for the full year and the fourth quarter. Since it provides a detailed breakdown of financial results and management's analysis of these figures, it is classified as a Management Discussion and Analysis (MDA) report, which is a core component of the annual reporting suite.
2025-03-03 English
Annual Report 2023
Annual Report Classification · 100% confidence The document is a segment of the Idorsia Annual Report 2023, specifically the 'Financial Review' section. It contains detailed financial tables, including profit and loss, cash flow, and operational performance metrics for the full year and the fourth quarter. Since it provides substantive financial data and analysis rather than just an announcement or a summary, it is classified as an Annual Report (10-K). FY 2023
2024-05-20 English
Annual Report 2022
Annual Report Classification · 100% confidence The document is titled 'Idorsia Annual Report 2022' and contains comprehensive financial sections including a 'Financial Review', 'Consolidated Financial Statements', and 'Holding Company Financial Statements'. It provides detailed financial data, including profit and loss, cash flow, and balance sheet information for the fiscal year 2022. As it is a full annual report containing audited financial statements and management analysis, it is classified as a 10-K (Annual Report). FY 2022
2023-02-06 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.